For example,
What if they linked better:
Essential
- The analogues of Glucagon-Like Peptide-1 (GLP-1), known as Ozempic, Mounjaro or Wegovy, are indicated in the management of diabetes and obesity. Furthermore,
- These drugs seem to have beneficial effects on the control of asthma in obese people. Nevertheless,
- More specifically, they “act on the inflammatory responses of the respiratory tract differently from the traditionally used steroids.”

. Similarly,
Originally taken to fight against diabetes, the analogues of glucagon-like peptide-1 (GLP-1), known as Ozempic, Mounjaro or Wegovy, are now prescribed in the event of obesity. However, The reason is simple: these treatments promote weight loss by regulating blood sugar, insulin and appetite. The latter are also known to reduce inflammatory cells by multiple signaling paths. In a new study. scientists The University of Aberdeen and what if they linked better the Observational and Pragmatic Research Institute (OPRI) of Singapore wanted to know if this mechanism had a positive impact on the respiratory tract.

.
Asthma: a drop in steroid prescriptions thanks to antidiabetics – What if they linked better
For the needs of the work, published in the journal Advances in Therapythe team used a database of primary care patients containing more than 28 million patients. She then analyzed the medical records of 10,111 adults using analogues of glucagon-like peptide-1 and 50,555 volunteers not using it. “The sample had a higher BMI and less controlled asthma.” The authors compared the measures of the severity of asthma between the participants in an entire year.

.
According to the results, obese and asthmatic patients taking analogues of glucagon-like peptide-1 have lost more weight than those who did not use it. With regard to asthma measures. namely steroid and drug prescriptions, they were also reduced in the group using Ozempic, Mounjaro what if they linked better or Wegovy. Clearly, their asthma was better controlled thanks to these treatments.

.
“GLP1 act on the inflammatory responses of the respiratory tract differently from steroids”
The authors suggest that the analogues of glucagon-like peptide-1 should be considered as a potential treatment of respiratory diseases. “Obese and asthmatic people are unique in the sense that they are often resistant to steroid treatments. We know that GLP1 act on the inflammatory responses of the respiratory tract differently from traditionally used steroids. In addition. it is important to note that the beneficial effects on the symptoms of asthma have occurred despite a relatively modest weight loss, of around 0.9 kg over the year. (…) This information should feed the discussions surrounding the decision to use these drugs, “ concluded the researchers.
what if they linked better
Further reading: “Our brains have aged even without infection”: what a long-awaited post-Covid-19 study reveals – CDCs have updated the list of countries where the number of dengue cases is currently higher than usual than – Morocco: the 1st publication in Advances in Radiation ONCOLOGY | Apanews – Alberta exceeds the United States with more than 1,300 cases of confirmed measles – Vigilance in the face of hepatitis has.